NCT06089265View on ClinicalTrials.gov

Ketohexokinase Inhibition in Hereditary Fructose Intolerance

PHASE2CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

HFI

Interventions

DRUG

PF-06801591

Active ketohexokinase inhibitor

Trial Locations (1)

6202AZ

Maastricht University Medical centre, Maastricht

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Maastricht University Medical Center

OTHER

NCT06089265 - Ketohexokinase Inhibition in Hereditary Fructose Intolerance | Biotech Hunter | Biotech Hunter